000293933 001__ 293933
000293933 005__ 20250218151253.0
000293933 0247_ $$2doi$$a10.1093/eurjpc/zwae315
000293933 0247_ $$2pmid$$apmid:39365172
000293933 0247_ $$2ISSN$$a2047-4873
000293933 0247_ $$2ISSN$$a2047-4881
000293933 0247_ $$2altmetric$$aaltmetric:168995783
000293933 037__ $$aDKFZ-2024-02000
000293933 041__ $$aEnglish
000293933 082__ $$a610
000293933 1001_ $$aShi, Fanchao$$b0
000293933 245__ $$aAssociation of circulating fatty acids with cardiovascular disease risk: Analysis of individual-level data in three large prospective cohorts and updated meta-analysis.
000293933 260__ $$aOxford$$bOxford University Press$$c2025
000293933 3367_ $$2DRIVER$$aarticle
000293933 3367_ $$2DataCite$$aOutput Types/Journal article
000293933 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1739887927_5678
000293933 3367_ $$2BibTeX$$aARTICLE
000293933 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000293933 3367_ $$00$$2EndNote$$aJournal Article
000293933 500__ $$a2025 Feb 18;32(3):233-246
000293933 520__ $$aAssociations of saturated and unsaturated fatty acids (FAs) with cardiovascular disease (CVD) remain controversial. We therefore aimed to investigate the prospective associations of objectively measured FAs with CVD, including incident coronary heart disease (CHD) and stroke, as well as CVD mortality.Circulating FA concentrations expressed as the percentage of total FAs were assayed in 172,891 participants without prior vascular disease at baseline from the European Prospective Investigation into Cancer and Nutrition-CVD (EPIC-CVD) (7,343 CHD; 6,499 stroke), UK Biobank (1,825; 1,474), and INTERVAL (285; 209) cohort studies. Hazard ratio (HR) per 1-standard deviation (SD) higher FA concentrations was estimated using Cox regression models and pooled by random-effects meta-analysis. Systematic reviews with meta-analysis published by 6 May 2023 on associations between FAs and CVDs were systematically searched and updated meta-analyses using random-effects model were conducted. Evidence from randomized controlled trials (RCTs) was also summarized.Higher concentrations of total saturated FAs (SFAs) were associated with higher cardiovascular risks in the combined analysis, with differential findings noted for SFA subtypes in further analysis restricted to EPIC-CVD: positive associations for even-chain SFA [HR for CHD 1.24 (95% CI: 1.18-1.32); stroke 1.23 (1.10-1.38)] and negative associations for odd-chain [0.82 (0.76-0.87); 0.73 (0.67-0.78)] and longer-chain [0.95 (0.80-1.12); 0.84 (0.72-0.99)] SFA. In the combined analysis, total n-3 polyunsaturated FA (PUFA) [0.91 (0.85-0.97)], including docosahexaenoic acid (DHA) [0.91 (0.84-0.98)], was negatively associated with incident CHD risk. Similarly, total n-6 PUFA [0.94 (0.91-0.98)], including linoleic acid (LA) [0.89 (0.83-0.95)], was negatively associated with incident stroke risk. By contrast, more detailed analyses in EPIC-CVD revealed that several downstream n-6 PUFAs of LA were positively associated with CHD risk. Updated meta-analyses of 37 FAs including 49 non-overlapping studies, involving between 7,787 to 22,802 CHD and 6,499 to 14,221 stroke cases, showed broadly similar results as our combined empirical analysis and further suggested significant inverse associations of individual long-chain n-3 PUFAs and LA on both CHD and stroke. The findings of long-chain n-3 PUFAs were consistent with those from published RCTs on CHD despite insufficient evidence in monotherapy, while RCT evidence remained unclear for the rest of the explored FAs.Our study provides an overview of the most recent evidence on the associations between objectively measured FAs and CVD outcomes. Collectively, the data reveals notable differences in associations by SFA subtypes and calls for further studies, especially RCTs, to explore these links.
000293933 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000293933 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000293933 7001_ $$aChowdhury, Rajiv$$b1
000293933 7001_ $$aSofianopoulou, Eleni$$b2
000293933 7001_ $$00000-0001-9998-051X$$aKoulman, Albert$$b3
000293933 7001_ $$aSun, Luanluan$$b4
000293933 7001_ $$aSteur, Marinka$$b5
000293933 7001_ $$00000-0002-1275-1827$$aAleksandrova, Krasimira$$b6
000293933 7001_ $$00000-0003-0481-2893$$aDahm, Christina C$$b7
000293933 7001_ $$aSchulze, Matthias B$$b8
000293933 7001_ $$avan der Schouw, Yvonne T$$b9
000293933 7001_ $$00000-0003-4472-1179$$aAgnoli, Claudia$$b10
000293933 7001_ $$aAmiano, Pilar$$b11
000293933 7001_ $$aBoer, Jolanda M A$$b12
000293933 7001_ $$aBork, Christian S$$b13
000293933 7001_ $$aCabrera-Castro, Natalia$$b14
000293933 7001_ $$aEichelmann, Fabian$$b15
000293933 7001_ $$00000-0001-9724-5490$$aElbaz, Alexis$$b16
000293933 7001_ $$aFarràs, Marta$$b17
000293933 7001_ $$00000-0001-6517-1300$$aHeath, Alicia K$$b18
000293933 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b19$$udkfz
000293933 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b20$$udkfz
000293933 7001_ $$aKeski-Rahkonen, Pekka$$b21
000293933 7001_ $$00000-0002-5758-9069$$aMasala, Giovanna$$b22
000293933 7001_ $$aMoreno-Iribas, Conchi$$b23
000293933 7001_ $$aPanico, Salvatore$$b24
000293933 7001_ $$00000-0002-4102-6835$$aPapier, Keren$$b25
000293933 7001_ $$aPetrova, Dafina$$b26
000293933 7001_ $$aQuirós, J Ramón$$b27
000293933 7001_ $$00000-0001-8749-9737$$aRicceri, Fulvio$$b28
000293933 7001_ $$aSeveri, Gianluca$$b29
000293933 7001_ $$00000-0003-4385-2097$$aTjønneland, Anne$$b30
000293933 7001_ $$aTong, Tammy Y N$$b31
000293933 7001_ $$00000-0003-2666-414X$$aTumino, Rosario$$b32
000293933 7001_ $$aWareham, Nick$$b33
000293933 7001_ $$aWeiderpass, Elisabete$$b34
000293933 7001_ $$00000-0001-8776-6719$$aDi Angelantonio, Emanuele$$b35
000293933 7001_ $$00000-0002-5041-248X$$aForouhi, Nita$$b36
000293933 7001_ $$aDanesh, John$$b37
000293933 7001_ $$aButterworth, Adam S$$b38
000293933 7001_ $$00000-0002-1155-4872$$aKaptoge, Stephen$$b39
000293933 773__ $$0PERI:(DE-600)2646239-4$$a10.1093/eurjpc/zwae315$$gp. zwae315$$n3$$p233-246$$tEuropean journal of preventive cardiology$$v32$$x2047-4873$$y2025
000293933 909CO $$ooai:inrepo02.dkfz.de:293933$$pVDB
000293933 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000293933 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000293933 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000293933 9141_ $$y2024
000293933 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-24$$wger
000293933 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J PREV CARDIOL : 2022$$d2023-08-24
000293933 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000293933 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000293933 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000293933 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000293933 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000293933 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000293933 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-24
000293933 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J PREV CARDIOL : 2022$$d2023-08-24
000293933 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000293933 980__ $$ajournal
000293933 980__ $$aVDB
000293933 980__ $$aI:(DE-He78)C020-20160331
000293933 980__ $$aUNRESTRICTED